Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs BYVALSON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
FDA-approved for the treatment of hypertension, heart failure (NYHA class II-IV), and to reduce cardiovascular mortality in stable post-myocardial infarction patients with left ventricular dysfunction or failure.,Off-label uses include diabetic nephropathy, prevention of atrial fibrillation recurrence, and migraine prophylaxis.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
160 mg orally once daily.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Valsartan is primarily metabolized by CYP2C9 and minimally by CYP3A4. It undergoes glucuronidation via UGT1A3, UGT1A9, and UGT2B7. The major metabolite is inactive.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
95% bound primarily to albumin
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Vd 8-10 L/kg; suggests extensive extravascular distribution
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral: 50% (range 40-60%); food reduces peak concentration but not AUC
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dosage adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Contraindicated in severe hepatic impairment (Child-Pugh class C); no adjustment for mild to moderate impairment (Child-Pugh A or B).
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Safety and efficacy not established in pediatric patients.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No specific dose adjustment recommended; initiate cautiously due to potential for decreased renal function.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal malformations, oligohydramnios, and neonatal renal failure. Discontinue as soon as pregnancy is detected.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypotension in volume- or salt-depleted patients,Hyperkalemia, especially with renal impairment, diabetes, or concomitant potassium-sparing diuretics,Renal function impairment, including acute renal failure,Angioedema (rare),Use caution in severe aortic stenosis,Avoid concomitant use with aliskiren in diabetic patients
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Pregnancy (absolute),History of angioedema from any ARB or ACE inhibitor,Concomitant use with aliskiren in diabetic patients (absolute),Severe hepatic impairment (Child-Pugh class C) (relative)
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium chloride, as BYVALSON can increase potassium levels.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. Risk is highest in the second and third trimesters; first-trimester exposure may also increase risk of congenital malformations.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No data on Byvalson (valsartan/nebivolol) in breast milk. Valsartan is excreted in rat milk; unknown in humans. Nebivolol is likely excreted in human milk. Due to potential for adverse effects in nursing infants (hypotension, bradycardia), breastfeeding is not recommended. M/P ratio not established.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Byvalson is contraindicated in pregnancy; no dose adjustment is recommended. Alternative antihypertensives with established safety profiles should be used. If exposure occurs, discontinue immediately and manage with appropriate therapy.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
BYVALSON (sacubitril/valsartan) is a first-in-class ARNI approved for heart failure with reduced ejection fraction (HFr EF). Monitor blood pressure and renal function closely upon initiation, especially in patients on high-dose ACE inhibitors or ARBs. Avoid use with ACE inhibitors within 36 hours due to risk of angioedema. May cause hypotension, hyperkalemia, and renal impairment. Titrate every 2-4 weeks to target dose of 97/103 mg BID as tolerated.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Do not take within 36 hours of any ACE inhibitor medication.,Take BYVALSON twice daily with or without food.,Monitor blood pressure regularly; report dizziness or fainting.,Avoid salt substitutes containing potassium.,Seek medical help immediately if you experience swelling of the face, lips, or throat.,Stay hydrated but do not use potassium supplements without consulting your doctor.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs BYVALSON, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. BYVALSON is a Angiotensin II Receptor Blocker that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and BYVALSON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of BYVALSON is: 160 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and BYVALSON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. BYVALSON is classified as Category C. Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypoten. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.